Neurogene (NGNE) Financials: Revenue & Earnings
NGNE$30.25+3.26 +12.09%
$478.07M
Market Cap
—
P/E
—
Forward P/E
—
Score
Neurogene (NGNE) Financials: Revenue & Earnings
NGNE price $30.25 +3.26 +12.09%
- Ticker
- NGNE
- Price
- $30.25
- Change
- +3.26 +12.09%
- Market cap ?
- $478.07M
- Beta ?
- 2.09
- Sector
- Healthcare
- Industry
- Biotechnology
Fair value
NGNE fair value $104.80. Price $30.25. Price is 71% below fair value.
Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.
Calculated with a 10-year free-cash-flow discount. Starting free cash flow 254.46K. Growth 11.32%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 12.00% (beta 2.0). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 15.80M. Net debt -93.95M. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the stock's own 10-year median P/E, kept between 8 and 40. Fewer than five years of history uses the sector's typical P/E. Fair value is the average of the cash-flow value and the earnings value when both exist. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.
Model uncertainty high for this stock
Earnings
| Date | EPS actual | EPS estimate | Revenue | Revenue estimate |
|---|---|---|---|---|
| 2026-11-12 | — | -1.49 | — | — |
| 2026-08-11 | -1.53 | -1.42 | — | — |
| 2026-05-12 | -1.39 | -1.30 | — | — |
| 2026-03-24 | -1.12 | -1.24 | — | — |
| 2025-11-14 | -0.99 | -1.26 | — | — |
| 2025-08-11 | -1.05 | -1.15 | — | — |
| 2025-05-09 | -1.08 | -1.05 | — | — |
| 2025-03-24 | -0.99 | -1.04 | — | — |
| 2024-11-18 | -1.19 | -1.22 | — | — |
| 2024-08-09 | -1.09 | -1.05 | 925.00K | — |
| 2024-05-09 | -1.00 | -1.13 | — | — |
| 2024-03-18 | -1.51 | -1.17 | — | — |
| 2023-11-14 | -2.47 | -0.60 | — | — |
| 2023-08-10 | -0.21 | -0.80 | — | — |
| 2023-05-08 | -5.20 | -4.40 | — | — |
| 2023-03-20 | -4.80 | -3.80 | — | — |
| 2022-11-14 | -4.80 | -6.09 | — | — |
| 2022-08-09 | -5.60 | -6.00 | — | — |
| 2022-05-09 | -5.60 | -5.96 | — | — |
Dividends
Yield 0.00%. Payout ratio 0.00%. Frequency —.
Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.
| Ex-date | Dividend | Record | Payment | Frequency |
|---|---|---|---|---|
| No data yet. | ||||
Insider trades
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-09-22 | McMinn Rachel | Buy | 756 | $25.32 | 19.14K |
| 2026-09-22 | McMinn Rachel | Sell | 756 | $25.32 | 19.14K |
| 2026-07-07 | Cvijic Christine Mikail | Sell | 4.20K | $36.13 | 151.76K |
| 2026-07-06 | Cvijic Christine Mikail | Sell | 600 | $36.02 | 21.61K |
| 2026-07-02 | Cvijic Christine Mikail | Sell | 2.53K | $34.58 | 87.52K |
| 2026-07-02 | Cvijic Christine Mikail | Sell | 1.53K | $35.23 | 53.90K |
| 2026-07-01 | Cvijic Christine Mikail | Sell | 739 | $34.06 | 25.17K |
| 2026-05-06 | Cvijic Christine Mikail | Sell | 4.80K | $30.07 | 144.35K |
| 2026-05-06 | Cvijic Christine Mikail | Sell | 4.80K | $32.44 | 155.69K |
| 2026-05-05 | Shafer Christina | Buy | 120.00K | $28.94 | 3.47M |
| 2026-04-20 | Shafer Christina | Other | 0 | — | — |
| 2026-03-26 | Cvijic Christine Mikail | Sell | 2.56K | $21.62 | 55.32K |
| 2026-03-26 | McMinn Rachel | Sell | 3.35K | $22.07 | 74.00K |
| 2026-03-26 | Jordan Julie | Sell | 828 | $21.89 | 18.13K |
| 2026-03-13 | Cobb Stuart | Sell | 3.99K | $20.41 | 81.46K |
| 2026-03-13 | Cobb Stuart | Sell | 2.66K | $21.34 | 56.72K |
| 2026-03-13 | Cobb Stuart | Sell | 148 | $22.08 | 3.27K |
| 2026-03-13 | Cvijic Christine Mikail | Sell | 2.39K | $20.42 | 48.75K |
| 2026-03-13 | Cvijic Christine Mikail | Sell | 1.40K | $21.25 | 29.64K |
| 2026-03-13 | Cvijic Christine Mikail | Sell | 263 | $22.02 | 5.79K |
| 2026-02-27 | Cvijic Christine Mikail | Sell | 4.80K | $25.11 | 120.53K |
| 2026-02-20 | Cobb Stuart | Buy | 16.50K | — | — |
| 2026-02-20 | Jordan Julie | Buy | 29.60K | $17.64 | 522.14K |
| 2026-02-20 | Jordan Julie | Buy | 4.90K | — | — |
| 2026-02-20 | Cvijic Christine Mikail | Buy | 131.90K | $17.64 | 2.33M |
| 2026-02-20 | Cvijic Christine Mikail | Buy | 22.00K | — | — |
| 2026-02-20 | McMinn Rachel | Buy | 25.90K | — | — |
| 2026-02-20 | McMinn Rachel | Buy | 155.10K | $17.64 | 2.74M |
| 2026-02-20 | PALEKAR ROHAN | Buy | 12.05K | $17.64 | 212.56K |
| 2026-02-20 | BAFFI ROBERT | Buy | 12.05K | $17.64 | 212.56K |
| 2026-02-20 | Noonberg Sarah B. | Buy | 12.05K | $17.64 | 212.56K |
| 2026-02-20 | Freedland Cory S. | Buy | 12.05K | $17.64 | 212.56K |
| 2026-02-20 | Woods Keith | Buy | 12.05K | $17.64 | 212.56K |
| 2025-06-12 | Woods Keith | Buy | 12.05K | $20.40 | 245.82K |
| 2025-06-12 | BAFFI ROBERT | Buy | 12.05K | $20.40 | 245.82K |
| 2025-06-12 | Woods Robert Keith | Buy | 12.05K | $20.40 | 245.82K |
| 2025-06-12 | PALEKAR ROHAN | Buy | 12.05K | $20.40 | 245.82K |
| 2025-06-12 | Freedland Cory S. | Buy | 12.05K | $20.40 | 245.82K |
| 2025-06-12 | Noonberg Sarah B. | Buy | 12.05K | $20.40 | 245.82K |
| 2025-05-14 | Cobb Stuart | Sell | 6.80K | $15.15 | 103.00K |
| 2025-03-26 | Cobb Stuart | Buy | 42.90K | $16.14 | 692.41K |
| 2025-03-26 | Cobb Stuart | Buy | 7.20K | — | — |
| 2025-03-26 | Cvijic Christine Mikail | Buy | 122.00K | $16.14 | 1.97M |
| 2025-03-26 | Cvijic Christine Mikail | Buy | 20.30K | — | — |
| 2025-03-26 | Jordan Julie | Buy | 50.30K | $16.14 | 811.84K |
| 2025-03-26 | Jordan Julie | Buy | 8.40K | — | — |
| 2025-03-26 | McMinn Rachel | Buy | 23.90K | — | — |
| 2025-03-26 | McMinn Rachel | Buy | 143.50K | $16.14 | 2.32M |
| 2025-03-13 | Cvijic Christine Mikail | Sell | 4.50K | $16.94 | 76.25K |
| 2024-11-26 | Samsara BioCapital GP, LLC | Buy | 2.00K | $27.50 | 55.00K |
| 2024-11-26 | Samsara BioCapital GP, LLC | Buy | 15.22K | $26.73 | 406.80K |
| 2024-11-26 | Samsara BioCapital GP, LLC | Buy | 10.80K | $26.01 | 280.99K |
| 2024-11-26 | Samsara BioCapital GP, LLC | Buy | 20.75K | $24.91 | 516.83K |
| 2024-11-25 | Samsara BioCapital GP, LLC | Other | 0 | — | — |
| 2024-11-25 | Samsara BioCapital GP, LLC | Other | 67.07K | — | — |
| 2024-11-25 | Samsara BioCapital GP, LLC | Other | 20.00K | $0.00 | 20 |
| 2024-11-22 | Cvijic Christine Mikail | Buy | 24.00K | $20.48 | 491.40K |
| 2024-11-22 | McMinn Rachel | Buy | 47.50K | $20.40 | 969.00K |
| 2024-06-14 | Woods Keith | Buy | 7.70K | $42.59 | 327.94K |
| 2024-06-14 | Woods Robert Keith | Buy | 7.70K | $42.59 | 327.94K |
| 2024-06-14 | PALEKAR ROHAN | Buy | 7.70K | $42.59 | 327.94K |
| 2024-06-14 | BAFFI ROBERT | Buy | 7.70K | $42.59 | 327.94K |
| 2024-06-14 | Noonberg Sarah B. | Buy | 7.70K | $42.59 | 327.94K |
| 2024-06-14 | Freedland Cory S. | Buy | 7.70K | $42.59 | 327.94K |
| 2024-03-13 | McMinn Rachel | Buy | 93.28K | $36.06 | 3.36M |
| 2024-03-13 | Cvijic Christine Mikail | Buy | 53.90K | $36.06 | 1.94M |
| 2024-03-13 | Cvijic Christine Mikail | Buy | 31.90K | — | — |
| 2024-03-13 | Cobb Stuart | Buy | 34.45K | $36.06 | 1.24M |
| 2024-03-13 | Cobb Stuart | Buy | 20.39K | — | — |
| 2024-01-16 | Woods Keith | Buy | 15.40K | $32.30 | 497.42K |
| 2023-12-18 | Woods Keith | Other | 0 | — | — |
| 2023-12-18 | BAKER BROS. ADVISORS LP | Buy | 1.15M | — | — |
| 2023-12-18 | BAKER BROS. ADVISORS LP | Buy | 221.56K | — | — |
| 2023-12-18 | BAKER BROS. ADVISORS LP | Buy | 310.13K | — | — |
| 2023-12-18 | BAKER BROS. ADVISORS LP | Buy | 973.29K | — | — |
| 2023-12-18 | BAKER BROS. ADVISORS LP | Buy | 93.48K | — | — |
| 2023-12-18 | BAKER BROS. ADVISORS LP | Buy | 20.56K | — | — |
| 2023-12-18 | BAKER BROS. ADVISORS LP | Buy | 28.78K | — | — |
| 2023-12-18 | BAKER BROS. ADVISORS LP | Buy | 78.33K | — | — |
Institutional holders
Latest filed quarter: Q2 2026.
Institutions holding: 117, holders +16 vs prior quarter. Ownership 76.92%.
| Holder | Shares | Change | Change % | Value |
|---|---|---|---|---|
| SAMSARA BIOCAPITAL, LLC | 1.72M | 0 | 0.00% | 54.00M |
| CASDIN CAPITAL, LLC | 1.55M | 125.00K | +8.80% | 48.60M |
| REDMILE GROUP, LLC | 1.41M | -47.40K | -3.25% | 44.41M |
| RTW INVESTMENTS, LP | 1.36M | 0 | 0.00% | 42.85M |
| ECOR1 CAPITAL, LLC | 1.27M | 0 | 0.00% | 39.98M |
| BLACKROCK, INC. | 1.06M | 52.91K | +5.26% | 33.27M |
| BAKER BROS. ADVISORS LP | 991.69K | 0 | 0.00% | 31.19M |
| BALYASNY ASSET MANAGEMENT L.P. | 818.71K | 100.32K | +13.96% | 25.75M |
| TRAILS EDGE CAPITAL PARTNERS, LP | 714.88K | -67.90K | -8.67% | 22.48M |
| TORONTO DOMINION BANK | 681.34K | 0 | 0.00% | 21.43M |
| VANGUARD CAPITAL MANAGEMENT LLC | 536.52K | 21.80K | +4.23% | 16.87M |
| JENNISON ASSOCIATES LLC | 518.58K | -9.10K | -1.73% | 16.31M |
| CITADEL ADVISORS LLC | 408.98K | 397.88K | +3584.52% | 12.86M |
| GREAT POINT PARTNERS LLC | 352.18K | -147.82K | -29.56% | 11.08M |
| ARROWMARK COLORADO HOLDINGS LLC | 342.45K | -182.34K | -34.75% | 10.77M |
| FMR LLC | 295.56K | -87.09K | -22.76% | 9.30M |
| GEODE CAPITAL MANAGEMENT, LLC | 293.18K | 14.18K | +5.08% | 9.22M |
| STATE STREET CORP | 224.32K | -88.68K | -28.33% | 7.05M |
| FRANKLIN TEMPLETON INC | 204.28K | 204.28K | New | 6.42M |
| MORGAN STANLEY | 191.72K | -93.52K | -32.78% | 6.03M |
| UBS GROUP AG | 171.29K | -14.39K | -7.75% | 5.39M |
| BLAIR WILLIAM & CO/IL | 146.91K | -21.31K | -12.67% | 4.62M |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 143.53K | 110.76K | +338.05% | 4.51M |
| POINT72 ASSET MANAGEMENT, L.P. | 141.92K | 141.92K | New | 4.46M |
| MOORE CAPITAL MANAGEMENT, LP | 141.64K | 141.64K | New | 4.45M |
Earnings and financials
Neurogene Inc. (NGNE) trades at $30.25, with a market cap of $478.07M and a trailing P/E of n/a. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Insights · Dividends · Forecast · Financials · Learn